INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
領航醫藥及生物科技有限公司
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2015The board (the 'Board') of directors (the 'Directors') of Innovative Pharmaceutical Biotech Limited (the 'Company', together with its subsidiaries, the 'Group') hereby announces the unaudited condensed consolidated interim results of the Group for the six months ended 30 September 2015 (the 'Financial Period') together with the comparative figures for the six months ended 30 September 2014 (the 'Previous Financial Period') as follows:
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOMEFor the six months ended 30 September 2015
Notes | 2015 HK$'000 (unaudited) | 2014 HK$'000 (unaudited) | |
Revenue | 3 | 14,817 | 18,185 |
Cost of sales and services | (14,390) | (17,845) | |
Gross profit | 427 | 340 | |
Other income | 6,312 | 1,754 | |
Other gains and losses, net | 4 | (46,086) | (313,905) |
Selling expenses | (126) | (727) | |
Administrative expenses | (8,991) | (16,324) | |
Other expenses | (6,528) | (4,050) | |
Share of results of associates | 4,556 | (755) | |
Finance costs | 5 | (37,832) | (15,974) |
Loss before tax Income tax | (88,268) - | (349,641) - | |
Loss for the period | 6 | (88,268) | (349,641) |
- 1 -
(\192.168.10.238productionjobs 3_annE_Ann20152427_E_Innovative Pharmaceutical IR2015)3rd Proof • 27 November 2015 • 18:45 27/11/2015 • 03G • Page 1
Six months ended 30 September 2015 2014HK$'000 HK$'000
Note (unaudited) (unaudited)
Other comprehensive (expense) income
Items that may be subsequently reclassified to
profit or loss: Fair value changes of available-for-sale financial assets | (915) | 163 | |
Reclassification adjustments for the cumulated loss upon disposal of available-for-sale financial assets | (37) | (1,274) | |
Exchange difference on translation of foreign operations | (295) | 10 | |
(1,247) | (1,101) | ||
Total comprehensive expense for the period | (89,515) | (350,742) | |
Loss for the period attributable to: Owners of the Company | (87,455) | (348,990) | |
Non-controlling interests | (813) | (651) | |
(88,268) | (349,641) | ||
Total comprehensive expense for the period attributable to: Owners of the Company | (88,702) | (350,091) | |
Non-controlling interests | (813) | (651) | |
(89,515) | (350,742) | ||
Loss per share Basic | 8 | HK(6.42) cents | HK(28.56) cents |
Diluted | HK(6.42) cents | HK(28.56) cents |
- 2 -
(\192.168.10.238productionjobs 3_annE_Ann20152427_E_Innovative Pharmaceutical IR2015)3rd Proof • 27 November 2015 • 18:45 27/11/2015 • 03G • Page 2
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITIONAt 30 September 2015
Notes | At 30 September 2015 HK$'000 (unaudited) | At 31 March 2015 HK$'000 (audited) | |
Non-current assets Property, plant and equipment | 35,934 | 36,346 | |
Interests in associates | 9 | 148,190 | 143,634 |
Investments in convertible bonds | 10 | 331,504 | 257,368 |
Intangible assets | 11 | 1,373,224 | 1,373,224 |
Available-for-sale financial assets | 6,835 | 6,887 | |
Loan to non-controlling interests | 4,065 | 3,557 | |
Amount due from the subsidiary of an associate | 14,169 | 10,378 | |
1,913,921 | 1,831,394 | ||
Current assets Trade receivables | 12 | 9,733 | 9,992 |
Prepayments, deposits and other receivables | 8,511 | 7,975 | |
Bank and cash balances | 147,454 | 191,191 | |
165,698 | 209,158 | ||
Current liabilities Trade payables | 13 | 4,645 | 7,099 |
Accruals and other payables | 10,285 | 9,217 | |
Amounts due to non-controlling interests | 22,871 | 22,871 | |
Amounts due to former non-controlling interests | 823 | 823 | |
Amount due to the subsidiary of an associate | 41,947 | 41,947 | |
80,571 | 81,957 | ||
Net current assets | 85,127 | 127,201 | |
Total assets less current liabilities | 1,999,048 | 1,958,595 |
- 3 -
(\192.168.10.238productionjobs 3_annE_Ann20152427_E_Innovative Pharmaceutical IR2015)3rd Proof • 27 November 2015 • 18:45 27/11/2015 • 03G • Page 3
Notes | At 30 September 2015 HK$'000 (unaudited) | At 31 March 2015 HK$'000 (audited) | |
Non-current liabilities Convertible bonds | 14 | 365,787 | 351,400 |
Deferred tax liabilities | 2,174 | 2,174 | |
Loan from a non-controlling interest | 4,065 | 3,557 | |
372,026 | 357,131 | ||
NET ASSETS | 1,627,022 | 1,601,464 | |
Capital and reserves Share capital | 14,042 | 13,042 | |
Reserves | 730,207 | 704,836 | |
Equity attributable to owners of the Company | 744,249 | 717,878 | |
Non-controlling interests | 882,773 | 883,586 | |
TOTAL EQUITY | 1,627,022 | 1,601,464 |
- 4 -
(\192.168.10.238productionjobs 3_annE_Ann20152427_E_Innovative Pharmaceutical IR2015)3rd Proof • 27 November 2015 • 18:45 27/11/2015 • 03G • Page 4
|
distributed by
|
